Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.68
- Piotroski Score 2.00
- Grade Overweight
- Symbol (MDXH)
- Company MDxHealth SA
- Price $1.89
- Changes Percentage (10.43%)
- Change $0.18
- Day Low $1.69
- Day High $1.89
- Year High $4.64
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $15.00
- High Stock Price Target $15.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.44
- Trailing P/E Ratio -2
- Forward P/E Ratio -2
- P/E Growth -2
- Net Income $-43,100,000
Income Statement
Quarterly
Annual
Latest News of MDXH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MDxHealth SA (MDXH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
Michael McGarrity, CEO, discusses a balanced strategy of internal and acquisition-driven development. Revenue growth is fueled by urology and pathology adoption, with focus on tissue-based tests. Mark...
By Yahoo! Finance | 2 weeks ago
